RBC Capital Raises PT on Boston Scientific Corporation (BSX) to $125 From $120

Boston Scientific Corporation (NYSE:BSX) is one of the top low volatility healthcare stocks to buy now. On July 24, RBC Capital raised the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $125 from $120, keeping an Outperform rating on the shares.

Was Jim Cramer Right About Boston Scientific Corporation (BSX)?

A surgeon examining a patient’s brain in an operating room, paramedics nearby.

The analyst told investors in a research note that Boston Scientific Corporation (NYSE:BSX) reported “impressive” Q2 results, raising its 2025 revenue growth and operating margin guidance.

The firm ranks Boston Scientific Corporation (NYSE:BSX) among the highest performing MedTech large-caps.

Boston Scientific Corporation (NYSE:BSX) reported its Q2 2025 earnings on July 23, with net sales for the quarter reaching $5.061 billion, growing 22.8% on a reported basis, 21.6% on an operational basis, and 17.4% on an organic basis, compared to the prior year period.

GAAP net income attributable to Boston Scientific Corporation (NYSE:BSX) common stockholders reached $797 million or $0.53 per share, compared to $324 million or $0.22 per share a year ago.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments.

The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.